摘要
目的探讨华法林在房颤患者抗凝治疗中的使用方法及临床效果,以减少房颤患者脑卒中的发生率,强调需密切监测标准化比值(INR),以减少华法林的不良反应。方法总结2004年5月至2009年5月使用华法林抗凝治疗的房颤患者60例,进行回顾性分析。结果房颤患者使用华法林抗凝治疗后脑卒中的年发生率为3.33%、无出血并发症的发生。结论无抗凝禁忌证的房颤患者,均应使用华法林抗凝治疗,但应密切监测服用期间国际标准化比率(INR),确保华法林的安全使用。
Objective To improve warfarin anticoagulation therapy in patients with atrial fibrillation in order to reduce the incidence of stroke. Stressed the needing to closely monitor the international normalized ratio （INR） and reduce the warfarin adverse reactions. Methods 60 cases from May 2004 to May 2009 with atrial fibrillation,who useed the warfarin anticoagulation therapy were analyzed retrospectively. Results Annual stroke incidence of patients with atrial fibrillation treated with warfarin was 3.33%, and no bleeding complications occurred. Conclusion Non-anticoagulant contraindications in patients with atrial fibrillation should use the warfarin anticoagulant therapy, but should be taken to closely monitor the international normalized ratio during the period （INR） to ensure the safe use of warfarin.
出处
《中国现代药物应用》
2010年第11期32-33,共2页
Chinese Journal of Modern Drug Application
关键词
华法林
心房颤动
抗凝治疗
Warfarin
Atrial fibrillation
Anticoagulation therapy
